JP2024521788A5 - - Google Patents

Info

Publication number
JP2024521788A5
JP2024521788A5 JP2023572798A JP2023572798A JP2024521788A5 JP 2024521788 A5 JP2024521788 A5 JP 2024521788A5 JP 2023572798 A JP2023572798 A JP 2023572798A JP 2023572798 A JP2023572798 A JP 2023572798A JP 2024521788 A5 JP2024521788 A5 JP 2024521788A5
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutical composition
composition according
kras
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521788A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030697 external-priority patent/WO2022251193A1/en
Publication of JP2024521788A publication Critical patent/JP2024521788A/ja
Publication of JP2024521788A5 publication Critical patent/JP2024521788A5/ja
Pending legal-status Critical Current

Links

JP2023572798A 2021-05-27 2022-05-24 併用療法 Pending JP2024521788A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163194140P 2021-05-27 2021-05-27
US63/194,140 2021-05-27
US202263329056P 2022-04-08 2022-04-08
US63/329,056 2022-04-08
PCT/US2022/030697 WO2022251193A1 (en) 2021-05-27 2022-05-24 Combination therapies

Publications (2)

Publication Number Publication Date
JP2024521788A JP2024521788A (ja) 2024-06-04
JP2024521788A5 true JP2024521788A5 (cg-RX-API-DMAC7.html) 2025-04-01

Family

ID=84229070

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572798A Pending JP2024521788A (ja) 2021-05-27 2022-05-24 併用療法

Country Status (5)

Country Link
US (2) US12280055B2 (cg-RX-API-DMAC7.html)
EP (1) EP4346826A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024521788A (cg-RX-API-DMAC7.html)
TW (1) TW202313050A (cg-RX-API-DMAC7.html)
WO (1) WO2022251193A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188383A4 (en) * 2020-07-28 2025-01-08 Mirati Therapeutics, Inc. SOS1 INHIBITORS
US20250059182A1 (en) * 2021-06-21 2025-02-20 Mirati Therapeutics, Inc. Sos1 inhibitors
CN118973580A (zh) * 2022-04-08 2024-11-15 米拉蒂治疗股份有限公司 包含sos1抑制剂和mek抑制剂的组合疗法
IL318882A (en) * 2022-08-19 2025-04-01 Mirati Therapeutics Inc Solid pharmaceutical preparations of Adagrasib
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
KR20260059498A (ko) * 2024-10-23 2026-04-30 제일약품주식회사 바이사이클릭 헤테로사이클릴 화합물의 신규 염 및 이의 결정형

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821963B2 (en) 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
WO2003077855A2 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP4931419B2 (ja) 2003-09-19 2012-05-16 中外製薬株式会社 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
EP1838675A1 (en) 2004-11-24 2007-10-03 Laboratoires Serono S.A. Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
US20060211073A1 (en) 2005-03-21 2006-09-21 May Earl W Assay for B-Raf activity based on intrinsic MEK ATPase activity
TWI441637B (zh) 2005-05-18 2014-06-21 Array Biopharma Inc Mek雜環抑制劑及其使用方法
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US20070172843A1 (en) 2005-09-12 2007-07-26 Conrad Susan E MEK interacting protein 1 as diagnostic and therapeutic target for breast cancer treatment and prevention
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
WO2007071951A1 (en) 2005-12-21 2007-06-28 Astrazeneca Ab Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
AU2007237901B2 (en) 2006-04-18 2012-07-05 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors
EA200802050A1 (ru) 2006-04-19 2009-04-28 Лаборатуар Сероно Са Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
WO2007123939A2 (en) 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
GB0625691D0 (en) 2006-12-22 2007-01-31 Astrazeneca Ab Combination product
ES2547303T3 (es) 2007-01-19 2015-10-05 Ardea Biosciences, Inc. Inhibidores de MEK
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
CA2694646C (en) 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
JP5615274B2 (ja) 2008-07-01 2014-10-29 ジェネンテック, インコーポレイテッド Mekキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
CA2727250A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
US8673919B2 (en) 2009-03-27 2014-03-18 Ardea Biosciences, Inc. Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors
CA2814617C (en) 2009-10-13 2017-12-19 Allostem Therapeutics Llc Novel mek inhibitors, useful in the treatment of diseases
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
US20120238599A1 (en) 2011-03-17 2012-09-20 Chemizon, A Division Of Optomagic Co., Ltd. Heterocyclic compounds as mek inhibitors
MA37405A1 (fr) 2012-03-14 2016-03-31 Lupin Ltd Composés hétérocyclyle
CA3079071C (en) 2012-10-19 2022-06-07 Array Biopharma Inc. Preparation of crystallized benzimidazole derivative as mek inhibitor and formulation comprising same
US9556112B2 (en) 2012-11-15 2017-01-31 Duquesne University Of The Holy Ghost Carboxylic acid ester prodrug inhibitors of MEK
WO2014204263A1 (en) 2013-06-20 2014-12-24 The Asan Foundation Substituted pyridinone compounds as mek inhibitors
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
BR112017018580A2 (pt) 2015-03-27 2018-04-24 Jiangsu Hengrui Medicine Co., Ltd. p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal
US10350198B2 (en) 2015-05-28 2019-07-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition of MEK inhibitor and preparation method thereof
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
EP3558979B1 (en) * 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
CA3082579A1 (en) * 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
IL317393A (en) 2018-12-21 2025-02-01 Revolution Medicines Inc Compounds that participate in covalent bonds and their uses
CA3157789A1 (en) * 2019-10-15 2021-04-22 Bayer Aktiengesellschaft 2-methyl-aza-quinazolines
PH12022551513A1 (en) * 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
IL295117A (en) * 2020-01-31 2022-09-01 Verastem Inc Combinations containing kras g12c inhibitors for the treatment of abnormal cell growth
JP2023531049A (ja) * 2020-06-24 2023-07-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sos1阻害剤及びkras g12c阻害剤を含む抗がん剤併用療法
KR20230137368A (ko) * 2021-01-19 2023-10-04 루핀 리미티드 암을 치료 및/또는 예방하기 위한 sos1 저해제들의약학적 조합물

Similar Documents

Publication Publication Date Title
JP2024537140A5 (cg-RX-API-DMAC7.html)
JP2025000629A5 (cg-RX-API-DMAC7.html)
JP2022548791A5 (cg-RX-API-DMAC7.html)
JP2025000632A5 (cg-RX-API-DMAC7.html)
JP2024537136A5 (cg-RX-API-DMAC7.html)
JP2024537139A5 (cg-RX-API-DMAC7.html)
JP2025000630A5 (cg-RX-API-DMAC7.html)
FI3849537T3 (fi) Yhdistelmäterapioita
JP2025512999A5 (cg-RX-API-DMAC7.html)
JP2024537137A5 (cg-RX-API-DMAC7.html)
JP2023540809A5 (cg-RX-API-DMAC7.html)
JP2024540839A5 (cg-RX-API-DMAC7.html)
IL311834A (en) Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods
JP2007533687A5 (cg-RX-API-DMAC7.html)
DK3027183T3 (en) SELECTIVE AT2 RECEPTOR AGONISTS FOR USING CACKSY TREATMENT
IL315645A (en) Combination therapies comprising a sos1 inhibitor and an egfr inhibitor
JP2022535577A5 (cg-RX-API-DMAC7.html)
IL311863A (en) Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods
JP2008540672A (ja) 病状に起因する性的機能不全の治療方法
JP2022530866A5 (cg-RX-API-DMAC7.html)
FI3518932T3 (fi) Eturauhassyövän hoito
CN103079564B (zh) 疼痛治疗剂
CN112292125B (zh) 蛋白尿的治疗
JP2025513802A5 (cg-RX-API-DMAC7.html)
TWI302912B (en) Therapeutic use